BioMarin Pharma Buys ZyStor Therapeutics

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) has acquired ZyStor Therapeutics Inc., a Milwaukee-based developer of enzyme replacement therapies for the treatment of lysosomal storage diseases. The deal is valued at up to $111 million, including a $22 million up-front payment and $93 million in earn-outs. ZyStor raised $8.5 million in VC funding in 2004, from Mason Wells, Venture Investors, Prolog Ventures, State of Wisconsin Investment Board, Hexagon Investments, Apjohn Ventures and Stonehenge Capital.

North AmericaUSBriefs